(Total Views: 709)
Posted On: 12/02/2020 6:27:21 AM
Post# of 145875
This is what every large Pharma facing patent expiration will try to do... they’re a plague (pun intended!)
Quote:
Still, last year, the FDA also approved Descovy, Gilead’s newest, pricier rival to Truvada; although Descovy results in some improved kidney function versus Truvada because it uses a newer type of tenofovir (tenofovir alafenamide instead of tenofovir disoproxil) patented by Gilead, a Harvard study found an “absence of any clinically meaningful changes in renal or bone markers” between the two. In January, Gilead still hoped to switch 40 to 45 percent of Truvada users to Descovy before the former goes fully generic at the end of 2020, preserving their profits.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)